PureTech Health PLC (GB:PRTC)
LSE:PRTC
Top Page
PureTech Health
(LSE:PRTC)
Select Model
Select Model
Rating:55Neutral
Price Target:
139.00 p
▲(3.12% Upside)
Action:ReiteratedDate:12/07/25
PureTech Health's overall score reflects a balance of strong liquidity and promising clinical developments against challenges in profitability and technical weakness. The company's strategic initiatives and recent positive trial results provide a cautiously optimistic outlook, but operational risks and funding uncertainties remain significant factors.
Positive Factors
Strong liquidity / runway
Nearly $320M in cash and short-term investments provides an operational runway into 2028, materially reducing near-term financing pressure. This durable liquidity supports continued R&D, clinical programs and spinouts, lowering dilution risk and enabling milestone-driven partnerships.
Negative Factors
Negative operating cash flow
Persistent negative operating cash flow and historically inconsistent free cash flow mean PureTech depends on financing and investing activities to fund operations. Over 2–6 months this raises dilution and refinancing risk, potentially constraining trial progress and the company’s ability to self‑fund spinouts.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong liquidity / runway
Nearly $320M in cash and short-term investments provides an operational runway into 2028, materially reducing near-term financing pressure. This durable liquidity supports continued R&D, clinical programs and spinouts, lowering dilution risk and enabling milestone-driven partnerships.
Read all positive factors
PureTech Health (PRTC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£275.06M
Dividend YieldN/A
Average Volume (3M)444.90K
Price to Earnings (P/E)―
Beta (1Y)1.48
Revenue Growth1231.50%
EPS GrowthN/A
CountryUK
Employees80
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding243,418,180
10 Day Avg. Volume437,187
30 Day Avg. Volume444,904
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.22
Price to Sales (P/S)117.44
P/FCF Ratio-3.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.65
Revenue Forecast (FY)£49.50M
PureTech Health Business Overview & Revenue Model
Company Description
PureTech Health (PRTC) is a biotechnology company focused on discovering, developing, and commercializing innovative therapies for serious diseases. The company operates primarily in the health and biotechnology sectors, leveraging its expertise i...
How the Company Makes Money
PureTech Health generates revenue through several key streams. Primarily, the company earns money by licensing its proprietary technologies and therapeutic candidates to larger pharmaceutical companies, which pay upfront fees and potential milesto...
PureTech Health Earnings Call Summary
Earnings Call Date:Aug 28, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Apr 23, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture. While PureTech demonstrated strong financial health and promising developments in its core programs, the recent management changes and ongoing efforts to secure external funding introduce some uncertainties. Overall, the company's strategic initiatives and financial position suggest a cautiously optimistic outlook.Positive Updates
Strong Financial Position
PureTech ended the half year with cash, cash equivalents, and short-term investments of just under $320 million, providing operational runway well into 2028.
Negative Updates
Management Changes
Recent management changes with an interim CEO and Chair, indicating potential instability or transition within the leadership team.
Read all updates
Q2-2025 Updates
Positive
Negative
Strong Financial Position
PureTech ended the half year with cash, cash equivalents, and short-term investments of just under $320 million, providing operational runway well into 2028.
Read all positive updates
Company Guidance
During the PureTech Health 2025 Half Year Earnings Webcast, the company provided detailed guidance on its strategic priorities and financial metrics. PureTech emphasized its commitment to developing new treatments, highlighted by the clinical progress of its lead program, deupirfenidone (LYT-100), and the launch of new entities Celea Therapeutics and Gallop Oncology. The company outlined three strategic pillars: advancing patient-focused treatments, strengthening engagement with U.K. capital markets, and employing a disciplined capital allocation approach. PureTech plans to appoint two new nonexecutive directors to enhance its board's expertise in U.K. capital markets. Financially, PureTech reported cash and short-term investments totaling just under $320 million, with an operational runway extending well into 2028. The company is focused on leveraging external capital to fund its spinout entities while maintaining significant economic interests, exemplified by its 35.1% equity stake in Seaport Therapeutics, which recently had a post-money valuation of $733 million.PureTech Health Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
50
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.88M | 4.32M | 750.00K | 2.09M | 9.98M | 8.34M |
| Gross Profit | 19.91M | 4.32M | -92.91M | -136.81M | -100.49M | 8.34M |
| EBITDA | 55.73M | 37.38M | -17.68M | -79.94M | -46.95M | -115.58M |
| Net Income | 50.68M | 53.51M | -65.70M | -50.35M | -60.56M | 5.99M |
Balance Sheet | ||||||
| Total Assets | 553.24M | 602.63M | 693.97M | 702.65M | 946.01M | 989.99M |
| Cash, Cash Equivalents and Short-Term Investments | 321.55M | 367.31M | 327.14M | 350.10M | 465.71M | 403.88M |
| Total Debt | 20.92M | 159.14M | 25.34M | 46.87M | 52.75M | 76.62M |
| Total Liabilities | 184.22M | 194.70M | 235.74M | 155.06M | 361.86M | 336.45M |
| Stockholders Equity | 375.98M | 414.71M | 464.07M | 542.22M | 593.51M | 669.75M |
Cash Flow | ||||||
| Free Cash Flow | -100.31M | -134.38M | -106.16M | -180.97M | -163.94M | -137.25M |
| Operating Cash Flow | -100.30M | -134.37M | -105.92M | -178.79M | -158.27M | -131.83M |
| Investing Cash Flow | 34.05M | 240.89M | 68.99M | -107.22M | 197.38M | 364.48M |
| Financing Cash Flow | 18.37M | -16.96M | 78.14M | -29.83M | 22.73M | 38.87M |
PureTech Health Technical Analysis
Negative
134.80
Price Trends
123.86
Negative
124.94
Negative
127.46
Negative
Market Momentum
-3.99
Positive
39.03
Neutral
23.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRTC, the sentiment is Negative. The current price of 134.8 is above the 20-day moving average (MA) of 116.97, above the 50-day MA of 123.86, and above the 200-day MA of 127.46, indicating a bearish trend. The MACD of -3.99 indicates Positive momentum. The RSI at 39.03 is Neutral, neither overbought nor oversold. The STOCH value of 23.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PRTC.
PureTech Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | £116.75M | -4.45 | 90.29% | ― | ― | -94.12% | |
56 Neutral | £24.92M | -1.64 | -197.54% | ― | 3.31% | 21.91% | |
55 Neutral | £275.06M | -2.25 | 12.82% | ― | 1231.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | £23.13M | -3.00 | 3817.30% | ― | ― | ― | |
42 Neutral | £277.75M | -1.74 | -361.23% | ― | ― | ― | |
41 Neutral | £74.95M | -4.89 | -63.53% | ― | 198.49% | -26.66% |
* Healthcare Sector Average
GB:PRTC
PureTech Health
113.00
-25.80
-18.59%
GB:AVCT
Avacta Group plc
63.50
29.75
88.15%
GB:IMM
ImmuPharma
4.60
1.95
73.58%
GB:SCLP
Scancell Holdings
11.25
3.10
38.04%
GB:4BB
4basebio UK Societas
484.00
-701.00
-59.16%
GB:AREC
Arecor Therapeutics PLC
66.00
24.50
59.04%
PureTech Health Corporate Events
Business Operations and Strategy
PureTech CEO to Present at J.P. Morgan Healthcare Conference
Positive
Jan 6, 2026
PureTech Health said its chief executive, Robert Lyne, will present at the 44th annual J.P. Morgan Healthcare Conference on 14 January 2026, with the presentation webcast available to investors online. Participation in the high-profile investor ev...
Business Operations and StrategyExecutive/Board Changes
PureTech Health Appoints Robert Lyne as CEO, Focuses on Strategic Growth
Positive
Dec 18, 2025
PureTech Health has announced the appointment of Robert Lyne as its new Chief Executive Officer and board member. Lyne, previously Interim CEO and Chief Portfolio Officer, is poised to lead the company towards a refined operational strategy focusi...
Executive/Board ChangesShareholder Meetings
PureTech Health Addresses Shareholder Concerns Post-AGM
Neutral
Dec 10, 2025
PureTech Health announced the results of its Annual General Meeting held on June 16, 2025, where all resolutions were approved, though more than 20% of votes were against the Directors’ Remuneration Report and the re-election of Ms. Mazumdar...
Business Operations and StrategyProduct-Related Announcements
PureTech Health Advances Deupirfenidone for IPF with FDA Support
Positive
Dec 8, 2025
PureTech Health announced a successful End-of-Phase 2 meeting with the FDA for deupirfenidone (LYT-100), a potential new standard of care for idiopathic pulmonary fibrosis (IPF). The FDA’s feedback supports the advancement into a pivotal Pha...
Business Operations and StrategyProduct-Related Announcements
PureTech’s Gallop Oncology Reports Positive Phase 1b Trial Results for LYT-200 in AML
Positive
Dec 5, 2025
Gallop Oncology, a PureTech Health entity, announced promising results from a Phase 1b trial of LYT-200, a monoclonal antibody for relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The trial showed LYT-...
Business Operations and StrategyProduct-Related Announcements
PureTech’s Gallop Oncology Reports Promising Results for LYT-200 in AML Trial
Positive
Nov 3, 2025
PureTech Health’s subsidiary, Gallop Oncology, announced promising new data from its Phase 1b trial of LYT-200, a monoclonal antibody, in treating relapsed/refractory acute myeloid leukemia (AML). The trial demonstrated significant clinical ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.